Patent intelligence · US
US 7344711
Use of adenoviruses mutated in the VA genes for cancer treatment
Use of adenoviruses mutated in the VA genes for cancer treatment
Patent details — US 7344711
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 18, 2008
- Expiration
- Mar 13, 2028
- Applicant
- ONCOLYTICS BIOTECH INC.
- Claims
- 15
- CPC classes
- A61K, A61K35/761, A61K48/00, A61P
Quick answer
US 7344711 (Use of adenoviruses mutated in the VA genes for cancer treatment) is held by ONCOLYTICS BIOTECH INC.. Status: granted. Granted Mar 18, 2008. Expires Mar 13, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ONCOLYTICS BIOTECH INC.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K35/761, A61K48/00, A61P, A61P35/00
More from ONCOLYTICS BIOTECH INC.
Related pharmaceutical patents in our USPTO index.
-
US 11542526
Oncolytic adenoviral vector and methods of use
granted -
US 11246930
Reoviruses having modified sequences
granted -
US 10596260
Reoviruses having modified sequences
granted -
US 10167452
Viral purification methods
granted -
US 10039827
Reoviruses having modified sequences
granted -
US 9610352
Lyophilized viral formulations
granted -
US 9610309
Liquid viral formulations
granted -
US 9365823
Virus clearance of neoplastic cells from mixed cellular compositions
granted
Frequently asked questions
What is US patent 7344711?
US 7344711 (Use of adenoviruses mutated in the VA genes for cancer treatment) is held by ONCOLYTICS BIOTECH INC.. Status: granted. Granted Mar 18, 2008. Expires Mar 13, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7344711?
ONCOLYTICS BIOTECH INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 66 pharmaceutical patents for this assignee.
When does US 7344711 expire?
Our index shows an expiration date of Mar 13, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.